Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer

被引：0
|
作者：
Valero, Vicente
Mouabbi, Jason
Alonzo, Heather
Pohlmann, Paula
Lheme, Adaeze
Hassan, Amy
Murthy, Rashmi
Huang, Xuelin
Qiao, Wei
Patel, Miral
Rauch, Gaiane
Checka, Cristina
Symmans, W. Fraser
Hunt, Kelly
Tripathy, Debu
Meric-Bernstam, Funda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS09-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS09-03
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor Positive, HER2 Negative Breast Cancer Patients
    Friedman-Eldar, O.
    Ozmen, T.
    Reyes, F. Valle
    Goel, N.
    Tjendra, Y.
    Moller, M.
    Kesmodel, S. B.
    Franceschi, D.
    Avisar, E.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S68 - S68
  • [2] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    [J]. BREAST, 2017, 32 : S18 - S18
  • [3] Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy
    Shi, Zhiqiang
    Wang, Xueer
    Qiu, Pengfei
    Liu, Yanbing
    Zhao, Tong
    Sun, Xiao
    Chen, Peng
    Wang, Chunjian
    Zhang, Zhaopeng
    Cong, Binbin
    Wang, Yongsheng
    [J]. GLAND SURGERY, 2021, 10 (01) : 166 - 174
  • [4] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    [J]. LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
  • [5] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [6] Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
    Alamoodi, Munaser
    Wazir, Umar
    Mokbel, Kinan
    Patani, Neill
    Varghese, Jajini
    Mokbel, Kefah
    [J]. CANCERS, 2023, 15 (13)
  • [7] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 26A - 26A
  • [8] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    [J]. MODERN PATHOLOGY, 2012, 25 : 26A - 26A
  • [9] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
    Sneha Phadke
    [J]. Current Oncology Reports, 2022, 24 : 1779 - 1789
  • [10] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345